CCF0058981

Research use only, not for human use.

CCF0058981 is a SARS-CoV-2 inhibitor with low nanomolar biochemical inhibition and efficacy in cellular models comparable to that of Remdesivir.

CCF0058981 is a SARS-CoV-2 inhibitor with low nanomolar biochemical inhibition and efficacy in cellular models comparable to that of Remdesivir.

CCF0058981 (CCF981) has cytopathic effect (CPE) inhibition (EC50=497 nM) and plaque reduction (EC50=558 nM) in vitro viral replication. CCF0058981 has the 50% cytotoxic concentration (CC50) in the CPE antiviral assay of >50 μM. CCF0058981 has a T1/2 of 21.1 min, a CLlnt of 141 mL/min?kg in Human liver microsomes.

——

——

Others

Other Targets

NF-κB|NOS|ROS

——

——

2708934-53-4

442.9

C24H19ClN6O

>98% (HPLC)

In Vitro:?DMSO : 25 mg/mL (56.45 mM)

O=C(N(C=1C=CC(=CC1)C2=CN=CN2)CC=3C=CC=C(Cl)C3)CN4N=NC=5C=CC=CC54

——

(-20℃)

With Ice Pack

≥ 2 years